Septerna announced the selection of oral small molecule SEP-204 as a disease-modifying candidate for Graves’ disease and TED, with preclinical data supporting once-daily dosing and a phase 1 trial planned for Q1 2027. The clinical-stage biotech's advancement of this novel treatment aims to address significant unmet needs in endocrinology.